CNTB241220P2500
- 0.00
- 0.000.00%
Connect Biopharma Newsroom
Connect Biopharma Hldgs Analyst Ratings
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for Connect Biopharma: Strategic Partnerships and Regulatory Progress Fuel Potential for Rademikibart
Connect Biopharma Hldgs Analyst Ratings
Connect Biopharma Hldgs Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
Buy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic Partnerships
Connect Biopharma Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Connect Biopharma Holdings (CNTB) and Inspire Medical Systems (INSP)
Cantor Fitzgerald Reiterates Overweight on Connect Biopharma Hldgs, Maintains $5 Price Target
Connect Biopharma Hldgs Analyst Ratings
SVB Securities Remains a Buy on Connect Biopharma Holdings (CNTB)
SVB Securities Adjusts Connect Biopharma Price Target to $7 From $9, Maintains Outperform Rating
Connect Biopharma Hldgs Analyst Ratings
SVB Leerink Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $7
Connect Biopharma Holdings (CNTB) Receives a Buy From Jefferies
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Rubius Therapeutics (RUBY) and Connect Biopharma Holdings (CNTB)
Piper Sandler Adjusts Price Target on Connect Biopharma Holdings to $1.75 From $1.50, Maintains Neutral Rating
SVB Securities Thinks Connect Biopharma Holdings' Stock is Going to Recover